A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
Price : $35 *
At a glance
- Drugs Sorafenib (Primary)
- Indications Thyroid cancer
- Focus Adverse reactions
- Sponsors Bayer
- 31 Aug 2018 Biomarkers information updated
- 26 Aug 2016 Status changed from active, no longer recruiting to completed.
- 25 May 2016 Planned End Date changed from 1 Aug 2016 to 1 Jul 2016.